Appendix 1. Proportion of Patients Vaccinated by Month*

Month (2021)	COH cohort	FET cohort
February	2.7% (5/179)	4.2% (5/119)
March	19.7% (36/183)	18.6% (21/113)
April	20.4% (33/162)	23.7% (33/139)
May	25.5% (47/184)	30.7% (46/150)
June	26.7% (8/30)	30.3% (23/76)
July	18.5% (37/200)	24.6% (33/134)
August	20.9% (28/134)	21.6% (29/134)
September	21.1% (28/133)	29.3% (24/82)
Total	18.4% (222/1205)	22.6% (214/947)

Data are percent (n)

*Data reflects first cycle for each patient within each cohort during the study period.

Appendix 2. Baseline Demographics, Cycle Characteristics, and Cycle Outcomes Among Vaccinated Patients Undergoing Controlled Ovarian Hyperstimulation Compared With a Propensity Score–Matched Unvaccinated Control Group (Matched for Age, Body Mass Index, Anti-Müllerian Hormone, Gravidity, Parity, Stimulation Type)

Variable	Vaccinated (n=222)	Unvaccinated (n=222)	P value
Age (yrs)	36.7±4.4	36.6±4.3	.95
BMI (kg/m^2)	24.3±4.6	24.3±4.4	.99
AMH (ng/ml)	2.9±2.9	2.8±2.8	.93
AFC	14.9±10.1	14.2±8.0	.77
Gravidity	0.0 (0.0-7.0)	0.0 (0.0-5.0)	.76
Parity	0.0 (0.0-3.0)	0.0 (0.0-4.0)	.81
Stimulation protocol			1.00
Antagonist	92.3%	92.3%	1.00
Flare	6.3%	6.3%	1.00
Down-regulation	1.4%	1.4%	1.00
Cumulative gonadotropin dosage (IU)	3954.0±1392.5	3857.8±1343.4	.46
Estradiol at trigger (pg/ml)	2559.4±1371.2	2500.7±1221.6	.89
Embryo biopsy for PGT-A	79.7%	83.3%	.33
Average biopsy day[*]			.78
5	59.9%	59.5%	
6	36.7%	35.7%	

Aharon D, Lederman M, Ghofranian A, Hernandez-Nieto C, Canon C, Hanley W, et al. In vitro fertilization and early pregnancy outcomes following after coronavirus disease 2019 (COVID-19) vaccination. Obstet Gynecol 2022;139. The authors provided this information as a supplement to their article.

7	3.4%	4.8%	
Fertilization rate	80.7% [78.4-83.0]	78.4% [75.8-81.0]	.38
Eggs retrieved	15.9 [14.4-17.5]	15.5 [14.2-16.8]	.77
MIIs retrieved	12.2 [11.0-13.3]	11.5 [10.4-12.5]	.70
MII ratio	77.2% [75.0-79.3]	74.3% [72.0-76.5]	.13
Blastulation rate	62.9% [59.4-66.4]	62.4% [58.9-65.9]	.89
Euploid rate[*]	48.8% [44.1-53.6]	42.8% [37.9-47.6]	.09

Data are mean±SD, median (range), or mean [95% confidence limits]

BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; PGT-A,

preimplantation genetic testing for aneuploidy

[*]Among cycles with embryo biopsy for PGT-A

Appendix 3. Baseline Demographics, Cycle Characteristics, and Pregnancy Outcomes Among Vaccinated Patients Undergoing Single Euploid Frozen Embryo Transfer Compared With a Propensity Score–Matched Unvaccinated Control Group (Matched for Age, Body Mass Index, Anti-Müllerian Hormone, Gravidity, Parity, Endometrial Thickness)

Variable	Vaccinated (n=214)	Unvaccinated (n=214)	P value
Age (yrs)	36.5±3.7	36.5±3.4	.98
Oocyte age (yrs)	35.7±3.6	35.6±3.5	.85
BMI (kg/m^2)	24.0±4.3	23.9±4.0	.95
AMH (ng/ml)	3.3±2.9	3.1±2.6	.55
AFC	14.4±9.4	13.5±7.8	.51
Gravidity	1.0 (0.0-7.0)	1.0 (0.0-6.0)	.95
Parity	0.0 (0.0-3.0)	0.0 (0.0-4.0)	.87
Endometrial thickness (mm)	9.6±2.2	9.6±2.0	.61
Embryo biopsy day			.94
5	55.1%	54.2%	
6	40.2%	41.6%	
7	4.7%	4.2%	
Expansion			.41
4	46.7%	40.7%	
5	25.7%	27.1%	
6	27.6%	32.2%	

Aharon D, Lederman M, Ghofranian A, Hernandez-Nieto C, Canon C, Hanley W, et al. In vitro fertilization and early pregnancy outcomes following after coronavirus disease 2019 (COVID-19) vaccination. Obstet Gynecol 2022;139. The authors provided this information as a supplement to their article.

ICM grade			.65
A	75.8%	77.1%	
B	19.4%	16.7%	
C	4.8%	6.2%	
TE grade			.91
A	41.0%	42.8%	
B	39.5%	38.9%	
C	19.5%	18.3%	
Clinical pregnancy rate	59.5% [52.7-66.3]	63.2% [56.7-69.8]	.44
Pregnancy rate	73.8% [67.9-79.8]	75.2% [69.4-81.1]	.74
Ongoing pregnancy rate	47.5% [40.4-54.5]	53.3% [46.3-60.3]	.25
Biochemical loss rate	17.1% [11.2-23.0]	15.5% [9.9-21.2]	.71
Clinical loss rate	18.0% [11.1-25.0]	12.0% [6.4-17.5]	.17

Data are mean±SD, median (range), or mean [95% confidence limits]

BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; ICM, inner

cell mass; TE, trophectoderm